Results 111 to 120 of about 28,764 (283)
Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury
OBJECTIVES: Cerebral edema is a key poor prognosticator in traumatic brain injury. There are no biomarkers identifying patients at-risk, or guiding mechanistically-precise therapies.
Chang, Chung-Chou H +23 more
core +1 more source
GLP‐1 Receptor Agonists Use in Patients With Prior Psychotropic Treatment: A Nationwide Cohort Study
ABSTRACT Aims Psychotropic medications are frequently associated with weight gain and metabolic syndrome. While GLP‐1 receptor agonists (GLP‐1RAs) have generated interest for managing these adverse effects, their current uses in psychiatric populations have to be described.
Nathan du Soulier +5 more
wiley +1 more source
BackgroundABCC8-maturity-onset diabetes of the young (ABCC8-MODY) is a rare monogenic diabetes with elusive genotype–phenotype correlations and frequent misdiagnosis as type 1 or type 2 diabetes. Adjudicating ABCC8 variants of uncertain significance (VUS)
Jiahui Chen +8 more
doaj +1 more source
ABSTRACT Aims Glucagon‐like peptide‐1‐based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide and semaglutide in Type 2 diabetes.
Tomoaki Morioka +14 more
wiley +1 more source
Background: Hypoglycemia has harmful effects on chronic complications of diabetes, and when it occurs at night, it is often asymptomatic. When oral hypoglycemic medications with different mechanisms of action that promote insulin secretion are used in ...
Tokio Sanke +3 more
doaj +1 more source
Resistance to sulfonylurea and imidazolinone herbicides can occur by mutations in acetohydroxyacid synthase (EC 4.1.3.18). Changing serine 653 to asparagine is known to cause insensitivity to imidazolinones but not to sulfonylureas.
Yu-Ting Lee +5 more
core +1 more source
ABSTRACT Aims Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown.
Gwen Aubrac +5 more
wiley +1 more source
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos +5 more
wiley +1 more source
Xiaomei Peng, Dingfeng Jiang, Dongju Liu, Oralee J Varnado, Jay P Bae Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA Background: Metformin is an oral antidiabetic drug (OAD) widely used as first-line ...
Peng X +4 more
core
ABSTRACT Aims Weight loss by laparoscopic sleeve gastrectomy (LSG) compared to medical weight loss (low‐calorie diet: LCD) ameliorates diabetes and metabolic dysfunction‐associated steatotic liver disease (MASLD). We aimed to evaluate changes in liver pathology 1‐year after LSG and their associations with metabolic factors in Japanese participants with
Daiki Matsubara +11 more
wiley +1 more source

